Blog

Vadim Koshkin: Our recent work highlighting a Grey Zone in metastatic urothelial carcinoma after enfortumab vedotin/pembrolizumab

Photo from Vadim Koshkin/X

Jun 1, 2024, 23:26

Vadim Koshkin: Our recent work highlighting a Grey Zone in metastatic urothelial carcinoma after enfortumab vedotin/pembrolizumab

Vadim Koshkin, Assistant Professor at University of California, San Francisco, shared a post on X/Twitter:

”Our recent work in European Urology Focus with Jason Brown, Case Comp Cancer Center highlighting a Grey Zone in metastatic urothelial carcinoma after enfortumab vedotin/pembrolizumab.

Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.”

Source: Vadim Koshkin/X

cancer Case Comp Cancer Center Enfortumab vedotin European Urology Focus Jason Brown metastatic urothelial carcinoma OncoDaily Oncology pembrolizumab University of California Vadim Koshkin

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity